Başlıca Eserleri

1. Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.  Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH, Paul JJ, Curado F, Skobalj S, Gaber H, Olmedillas M, Bogdanovic X, Ameziane N, Schell N, Aasly JO, Afshari M, Agarwal P, Aldred J, Alonso-Frech F, Anderson R, Araújo R, Arkadir D, Avenali M, Balal M, Benizri S, Bette S, Bhatia P, Bonello M, Braga-Neto P, Brauneis S, Cardoso FEC, Cavallieri F, Classen J, Cohen L, Coletta D, Crosiers D, Cullufi P, Dashtipour K, Demirkiran M, de Carvalho Aguiar P, De Rosa A, Djaldetti R, Dogu O, Dos Santos Ghilardi MG, Eggers C, Elibol B, Ellenbogen A, Ertan S, Fabiani G, Falkenburger BH, Farrow S, Fay-Karmon T, Ferencz GJ, Fonoff ET, Fragoso YD, Genç G, Gorospe A, Grandas F, Gruber D, Gudesblatt M, Gurevich T, Hagenah J, Hanagasi HA, Hassin-Baer S, Hauser RA, Hernández-Vara J, Herting B, Hinson VK, Hogg E, Hu MT, Hummelgen E, Hussey K, Infante J, Isaacson SH, Jauma S, Koleva-Alazeh N, Kuhlenbäumer G, Kühn A, Litvan I, López-Manzanares L, Luxmore M, Manandhar S, Marcaud V, Markopoulou K, Marras C, McKenzie M, Matarazzo M, Merello M, Mollenhauer B, Morgan JC, Mullin S, Musacchio T, Myers B, Negrotti A, Nieves A, Nitsan Z, Oskooilar N, Öztop-Çakmak Ö, Pal G, Pavese N, Percesepe A, Piccoli T, Pinto de Souza C, Prell T, Pulera M, Raw J, Reetz K, Reiner J, Rosenberg D, Ruiz-Lopez M, Ruiz Martinez J, Sammler E, Santos-Lobato BL, Saunders-Pullman R, Schlesinger I, Schofield CM, Schumacher-Schuh AF, Scott B, Sesar Á, Shafer SJ, Sheridan R, Silverdale M, Sophia R, Spitz M, Stathis P, Stocchi F, Tagliati M, Tai YF, Terwecoren A, Thonke S, Tönges L, Toschi G, Tumas V, Urban PP, Vacca L, Vandenberghe W, Valente EM, Valzania F, Vela-Desojo L, Weill C, Weise D, Wojcieszek J, Wolz M, Yahalom G, Yalcin-Cakmakli G, Zittel S, Zlotnik Y, Kandaswamy KK, Balck A, Hanssen H, Borsche M, Lange LM, Csoti I, Lohmann K, Kasten M, Brüggemann N, Rolfs A, Klein C, Bauer P. Brain. 2024 Aug 1;147(8):2652-2667.doi: 10.1093/brain/awae188.
2. The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis. Boz C, Ozakbas S, Terzi M, Karabudak R, Sevim S, Turkoglu R, Soysal A, Balcı BP, Efendi H, Turan ÖF, Yüceyar N, Yetkin MF, Karahan SZ, Demirkiran M, Guler S, Agan K, Kıylıoğlu N, Baba C, Tuncer A, Köseoğlu M. Neurol Sci. 2023 Jun;44(6):2121-2129.
3. Oromandibular Dystonia: Clinical and Demographic Data from Eight-Two Patients. Balal M, Demirkiran M. Tremor Other Hyperkinet Mov (N Y). 2023 Jan 30;13:3. doi: 10.5334/tohm.730.
4. Postural stability in blepharospasm: the effects of dual-tasking and botulinum toxin therapy. Balal M, Demir T, Erdem M, Demirkiran M. BMJ Neurol Open. 2023 Mar 10;5(1):e000403. doi: 10.1136/bmjno-2023-000403.
5. MYO1H is a novel candidate gene for autosomal dominant pure hereditary spastic paraplegia, Selcuk E., Kirimtay K., Temizci İmanç B., Akarsu Ş., Everest E., Baslo M. B., Demirkiran M., Yapici Z., Karabay Korkmaz A., Mol Genet Genomics. 2022 Jul;297(4):1141-1150. doi: 10.1007/s00438-022-01910-5. 
6. Central Aortic Pressure and Arterial Stiffness in Parkinson's Disease: A Comparative Study, Balal M., Demirkiran M., Paydaş S.  Parkinson Disease, 2022 Jul 12;2022:6723950. doi: 10.1155/2022/6723950.
7. The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course? Sen S, Tuncer A, Ozakbas S, Uzunkopru C, Baba C, Demir S, Beckmann Y, Gumus H, Arslan G, Kilic AK, Altintas A, Yuceyar N, Turan OF, Tutuncu M, Terzi M, Acar P, Bunul SD, Balci BP, Bir LS, Koseoglu M, Mungan S, Gunduz T, Dogan IG, Kotan D, Uygunoglu U, Ekmekci O, Demirkiran M, Kamisli O, Kabay SC, Tamam Y, Omerhoca S, Sevim S, Guler S, Kurtuncu M, Efendi H, Karabudak R, Siva A. Mult Scler Relat Disord. 2022 Feb;58:103399. doi: 10.1016/j.msard.2021.103399.
8. Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression, Sevim S., Demirkiran M., Terzi M., Yüceyar A. N., Tasdelen B., İdiman E., Kurtuncu M., Boz C., Tuncel D., Karabudak R., et al. Arq Neuropsiquiatr, 2022 Feb;80(2):168-172. doi: 10.1590/0004-282X-ANP-2020-0400.
9. 'Is RLS a harbinger and consequence of MS?: Striking results of the 'RELOMS-T' study'. Sevim S, Demirkiran M, Terzi M, Yüceyar N, Taşdelen B, İdiman E, Kürtüncü M, Boz C, Tuncel D, Karabudak R, Siva A, Özcan A, Neyal M, Göksel BK, Balal M, Şen S, Ekmekçi Ö, Öksüz N, Kaya D. Mult Scler Relat Disord. 2020 Jul;42:102055. doi: 10.1016/j.msard.2020.102055. 
10. Evaluation of postural balance in patients with obstructive sleep apnoea syndrome. Demir T, Aslan K, Demirkiran M. Neurol Neurochir Pol2020;54(1):83-89. doi: 10.5603/PJNNS.a2019.0059.
11. The effect of cognitive task on postural stability in cervical dystonia. Demİr T, Balal M, Demirkiran M. Arq Neuropsiquiatr. 2020 Sep;78(9):549-555. doi: 10.1590/0004-282X20200038.
12. Contribution of functional dopamine D2 and D3 receptor variants to motor and non-motor symptoms of early onset Parkinson's disease. Eryilmaz IE, Erer S, Zarifoglu M, Egeli U, Karakus E, Yurdacan B, Cecener G, Tunca B, Colakoglu B, Bora Tokcaer A, Saka E, Demirkiran M, Akbostanci C, Dogu O, Kaleagasi H, Kenangil G, Cakmur R, Elibol B. Clin Neurol Neurosurg. 2020 Dec;199:106257.
13. Comparative analysis of fingolimod versus teriflunomide in relapsing-remitting multiple sclerosis. Boz C, Terzi M, Özer B, Turkoglu R, Karabudak R, Efendi H, Soysal A, Sevim S, Altintas A, Kurne A, Akçalı A, Akman G, Yüceyar N, Balcı BP, Ekmekci Ö, Karahan SZ, Demirkıran M, Altunrende B, Turan ÖF, Gökçen GözübatıkÇelik, Kale N, Köseoğlu M, Ozakbas S. Mult Scler Relat Disord. 2019 Nov;36:101376. doi: 10.1016/j.msard.2019.101376. 
14. Epigenetic approach to early-onset Parkinson's disease: low methylation status of SNCA and PARK2 promoter regions. Eryilmaz IE, Cecener G, Erer S, Egeli U, Tunca B, Zarifoglu M, Elibol B, Bora Tokcaer A, Saka E, Demirkiran M, Akbostanci C, Dogu O, Colakoglu B, Kenangil G, Kaleagasi H. Neurol Res. 2017 Nov;39(11):965-972. doi: 10.1080/01616412.2017.1368141.
15. Evaluation of the Innermost Retinal Layers and Visual Evoked Potentials in Patients with Multiple Sclerosis. Esen E, Sizmaz S, Balal M, Yar K, Demirkiran M, Unal I, Demircan N. Curr Eye Res. 2016 Oct;41(10):1353-1358. doi: 10.3109/02713683.2015.1119283.
16. Evaluation of Choroidal Vascular Changes in Patients with Multiple Sclerosis Using Enhanced Depth Imaging Optical Coherence Tomography. Esen E, Sizmaz S, Demir T, Demirkiran M, Unal I, Demircan N. Ophthalmologica. 2016;235(2):65-71. doi: 10.1159/000441152.
17. Rare onset symptoms in multiple sclerosis. Evlice A, Demir T, Kaleağası C, Özcan F, Demirkıran M. Acta Clin Belg. 2016 Jun;71(3):154-7. doi: 10.1080/17843286.2016.1147675.
18. Prevalence and risk factors of low bone mineral density in patients with multiple sclerosis. Coskun Benlidayi I, Basaran S, Evlice A, Erdem M, Demirkiran M.Acta Clin Belg. 2015 Jun;70(3):188-92. doi: 10.1179/2295333715Y.0000000002.
19. A case of Cortical Multiple Sclerosis. Evlice A, Demirkiran M, Aslan K, Bozdemir H. Noro Psikiyatr Ars. 2014 Dec;51(4):408-409.
20. Crossed aphasia in Multiple Sclerosis. Demirkiran M, Ozeren A, Sönmezler A, Bozdemir H. Mult Scler. 2006 Feb;12(1):116-9. doi: 10.1191/135248506ms1255cr.
21. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Demirkiran M., Sarıca Y., Uğuz Ş., Yerdelen D., Aslan K. Mult Scler. 2006 Apr;12(2):209-14. doi: 10.1191/135248506ms1253oa.
22. A whole genome screen for linkage in Turkish multiple sclerosis. Eraksoy M, Kurtuncu M, Akman-Demir G, Kilinc M, Gedizlioglu M, Mirza M, Anlar O, Kutlu C, Demirkiran M, Idrisoglu HA, Compston A, Sawcer S; Turkish Multiple Sclerosis Genetics Study Group.J Neuroimmunol. 2003 Oct;143(1-2):17-24. doi: 10.1016/j.jneuroim.2003.08.006.
23. Classification of paroxysmal dyskinesias and ataxias Jankovic J., Demirkiran M. Adv Neurol. 2002;89:387-400.
24. The effects of cold stress test on vasomotor tonus in normal controls. Bozdemir H, Sarica Y, Demirkiran M.Neurol India. 2002 Dec;50(4):531-4.
25. Vascular parkinsonism: a distinct, heterogeneous clinical entity Demirkiran M, Bozdemir H, Sarica Y.Acta Neurol Scand. 2001 Aug;104(2):63-7. doi: 10.1034/j.1600-0404.2001.104002063.x.
26. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Kantarci O, Siva A, Eraksoy M, Karabudak R, Sütlaş N, Ağaoğlu J, Turan F, Ozmenoğlu M, Toğrul E, Demirkiran M. Neurology. 1998 Sep;51(3):765-72. doi: 10.1212/wnl.51.3.765.
27. Transesophageal echocardiography in various ischemic stroke subtypes. Ozeren A, Acartürk E, Sarica Y, Demirkiran M.Jpn Heart J. 1997 Mar;38(2):199-206. doi: 10.1536/ihj.38.199.
28. Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome ., Demirkiran M., Jankovic J., Dean J. Clin Neuropharmacol. 1996 Apr;19(2):157-64. doi: 10.1097/00002826-199619020-00004.
29. Neurologic presentation of Wilson disease without Kayser-Fleischer rings ., Demirkiran M., Jankovic J., Lewis R., Cox D. Neurology. 1996 Apr;46(4):1040-3. doi: 10.1212/wnl.46.4.1040.
30. Bromocriptine is ineffective in the treatment of chronic nonfluent aphasia. Ozeren A., Sarica Y., Mavi H., Demirkiran M. Acta Neurol Belg. 1995 Dec;95(4):235-8.
31. Paroxysmal dyskinesias: clinical features and classification. Demirkiran M, Jankovic J. Ann Neurol. 1995 Oct;38(4):571-9. doi: 10.1002/ana.410380405. 

Metrikler

• Yayın: 149
• Atıf (WoS): 977
• Atıf (Scopus): 1171
• Atıf (Google scholar): 2121
• H-İndeks (WoS): 12
• H-İndex (Google scholar): 16
• İ10-index (Google scholar): 22